Advertisement
BRTX vs VYGR
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BRTX is a Hold and VYGR is a Hold.
BRTX in downward trend: 10-day moving average crossed below 50-day moving average on September 18, 2026
The 10-day moving average for BRTX crossed bearishly below the 50-day moving average on September 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 21 of 22 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BRTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for BRTX entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for BRTX just turned positive on October 07, 2026. Looking at past instances where BRTX's MACD turned positive, the stock continued to rise in 34 of 41 cases over the following month. The odds of a continued upward trend are 83%.
Following a +8.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where BRTX advanced for three days, in 179 of 223 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
BRTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.698) is normal, around the industry mean (2.973). P/E Ratio (-1.443) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (4.055) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. BRTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BRTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
VYGR's RSI Indicator slumps oversold zone
The RSI Indicator for VYGR moved into overbought territory on October 22, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +15.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where VYGR advanced for three days, in 229 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
VYGR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day moving average for VYGR crossed bearishly below the 50-day moving average on September 17, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 17 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VYGR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for VYGR entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.742) is normal, around the industry mean (2.973). P/E Ratio (-1.028) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.070) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (5.263) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. VYGR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VYGR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
BRTX | VYGR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 61 | 66 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 38 Fair valued | 45 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 98 | |
PRICE GROWTH RATING 1..100 | 96 | 89 | |
P/E GROWTH RATING 1..100 | 100 | 14 | |
SEASONALITY SCORE 1..100 | 90 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BRTX's Valuation (38) in the null industry is in the same range as VYGR (45) in the Biotechnology industry. This means that BRTX’s stock grew similarly to VYGR’s over the last 12 months.
BRTX's Profit vs Risk Rating (100) in the null industry is in the same range as VYGR (100) in the Biotechnology industry. This means that BRTX’s stock grew similarly to VYGR’s over the last 12 months.
VYGR's SMR Rating (98) in the Biotechnology industry is in the same range as BRTX (100) in the null industry. This means that VYGR’s stock grew similarly to BRTX’s over the last 12 months.
VYGR's Price Growth Rating (89) in the Biotechnology industry is in the same range as BRTX (96) in the null industry. This means that VYGR’s stock grew similarly to BRTX’s over the last 12 months.
VYGR's P/E Growth Rating (14) in the Biotechnology industry is significantly better than the same rating for BRTX (100) in the null industry. This means that VYGR’s stock grew significantly faster than BRTX’s over the last 12 months.
| BRTX | VYGR | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 90% |
| Stochastic ODDS (%) | N/A | 1 day ago 83% |
| Momentum ODDS (%) | N/A | N/A |
| MACD ODDS (%) | 1 day ago 83% | N/A |
| TrendWeek ODDS (%) | 1 day ago 82% | 1 day ago 86% |
| TrendMonth ODDS (%) | 1 day ago 89% | 1 day ago 84% |
| Advances ODDS (%) | 4 days ago 80% | 3 days ago 83% |
| Declines ODDS (%) | 1 day ago 87% | 1 day ago 82% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 83% |
| Aroon ODDS (%) | 1 day ago 89% | 1 day ago 72% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BRTX’s FA Score shows that 0 FA rating(s) are green while VYGR’s FA Score has 1 green FA rating(s).
- BRTX’s FA Score: 0 green, 5 red.
- VYGR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BRTX’s TA Score shows that 3 TA indicator(s) are bullish while VYGR’s TA Score has 4 bullish TA indicator(s).
- BRTX’s TA Score: 3 bullish, 3 bearish.
- VYGR’s TA Score: 4 bullish, 3 bearish.
Price Growth
BRTX (@Biotechnology) experienced а +5.52% price change this week, while VYGR (@Biotechnology) price change was -9.71% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
Reported Earning Dates
BRTX is expected to report earnings on Nov 11, 2026.
VYGR is expected to report earnings on Nov 09, 2026.
Industries' Descriptions
@Biotechnology (-1.17% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| EWV | 16.92 | 0.42 | +2.57% |
| ProShares UltraShort MSCI Japan (EWV) | |||
| DYLD | 22.17 | 0.06 | +0.27% |
| LeaderShares Dynamic Yield ETF (DYLD) | |||
| CGCV | 33.24 | 0.09 | +0.27% |
| Capital Group Conservative Equity ETF (CGCV) | |||
| GJUL | 44.62 | -0.28 | -0.62% |
| FT Vest U.S. Equity Moderate Buffer ETF - July (GJUL) | |||
| EDC | 59.63 | -5.64 | -8.64% |
| Direxion Daily MSCI Emerging Markets Bull 3X ETF (EDC) | |||